glp-1 drugs key developments 2025 Market Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 GLP-1 Market Trends and Global
Description
Data from numerous clinical trials primarily evaluating the antihyperglycemic effects of multiple GLP-1 RAs have also revealed that changes in most CVD risk markers reported as secondary outcomes have been in favor of GLP-1 RAs treatment
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder A Randomized Clinical Trial
Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy
Prorenin Receptor Blockade Inhibits Development of Glomerulosclerosis in Diabetic Angiotensin II Type 1a Receptor-Deficient Mice
Clinical evidence for allulose and GLP-1 is mixed but cautiously positive
Researchers also found the proportion of users of GLP-1 medications without FDA-approved indications rose from 0.21% in 2019 to 0.37% in 2023
